argenx SE ADR Stock

$566.74

1.16% today

Nasdaq, Jul 14, 04:47 pm CET

ISIN

US04016X1019

Symbol

ARGX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

argenx SE ADR Stock price

$560.24

+309.42 123.36% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-3.07 0.55%

ISIN

US04016X1019

Symbol

ARGX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$34.7b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

34.6 | 47.9

P/S

13.5 | 9.6

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

88.7%

Return on Equity

15.2%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$2.6b | $3.6b

EBITDA

- | $808.8m

EBIT

$217.8m | $769.1m

Net Income

$1.1b | -

Free Cash Flow

EPS

$16.2

FCF per Share

Short interest

3.7%

Employees

Rev per Employee

$1.4m

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

argenx SE ADR Stock Analysis

Unlock Scores for Free

??

26 Analysts have issued a argenx SE ADR forecast:

24x Buy

92%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a argenx SE ADR forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2,580 2,580	- 100%
- Direct Costs	265 265	- 10%
Gross Profit	1,890 1,890	- 73%
- Selling and Administrative Expenses	1,096 1,096	- 42%
- Research and Development Expense	842 842	- 33%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	218 218	- 8%
Net Profit	1,064 1,064	- 41%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

argenx SE ADR Stock News

Neutral

GlobeNewsWire

●

24 days ago

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART ® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest study of CIDP patients to date First novel mechanism of action for CIDP treatment in more than 30 years June 20, 2025, 7:00 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ...

Neutral

GlobeNewsWire

●

about one month ago

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcomes in patients with Sjogren's disease; program granted U.S. FDA Fast Track designation argenx committed to new therapeutic areas in rheumatology with ongoin...

Neutral

GlobeNewsWire

●

about one month ago

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karl Gubitz, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40 AM ET in Miami, FL.

More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office	Netherlands
CEO	Tim Hauwermeiren
Employees	1,599
Founded	2008
Website	www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now